LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

Contributed by: Business Wire

Logo

Tags

Biotechnology

Medical Devices

Health

Optical

Clinical Trials

LIGHTSITE IIIB Extension Trial

More Like This

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

PR Newswire associated0

i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD

OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio

PR Newswire associated0

LUMA Vision Expands Clinical Use of VERAFEYE™ in Guiding AF Ablations and Completes Key 510k Submission.

Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy